Cambridge Cognition Holdings PLC New Major Pharma Client for Schizophrenia Trials (8378X)
10 Enero 2022 - 01:00AM
UK Regulatory
TIDMCOG
RNS Number : 8378X
Cambridge Cognition Holdings PLC
10 January 2022
Cambridge Cognition Holdings Plc
("Cambridge Cognition" or the "Company")
Cambridge Cognition announces new major pharma client for
schizophrenia clinical trials
Cambridge Cognition Holdings Plc (AIM: COG), which develops and
markets digital solutions to assess brain health, is pleased to
announce that it has been awarded contracts for two clinical trials
by a top 20 pharmaceutical company to assess the pro-cognitive
effects of a new drug in schizophrenia. Together the contracts are
worth GBP700,000 over two years. This is the second pharmaceutical
client to award Cambridge Cognition major contracts for cognitive
assessments for schizophrenia in the last year(1) . Approximately
30 clinical trials on new drugs for schizophrenia run every year(2)
, demonstrating the potential for further sales in this therapeutic
area.
Cambridge Cognition offers cognitive assessments with the
sensitivity to measure the distinct cognitive processes impaired in
schizophrenia, including memory, attention and executive function.
Between September 2020 and December 2021, the Company was
contracted for six pivotal trials for another client's new
schizophrenia drug(1) , earning Cambridge Cognition a reputation in
the field for delivering highly sensitive cognitive assessments.
Now, this new client, a top 20 pharmaceutical company has
contracted Cambridge Cognition to determine the efficacy of its new
drug for improving cognition in patients with schizophrenia and
another indication. Cambridge Cognition will provide its
proprietary cognitive assessments (CANTAB(TM) ), its electronic
questionnaires and scales platform (eCOA), and specialist, study
management services.
Matthew Stork, Chief Executive Officer of Cambridge Cognition,
said:
"It is excellent news that we have secured another top 20
pharmaceutical company as a new client and that we are conducting
more clinical trials for patients with schizophrenia, which is a
therapeutic area we are targeting for growth. We are pleased with
this client win which continues the very positive momentum in the
business and further improves our revenue visibility."
1. Announced by the Company on 1 September 2020, 30 March 2021,
26 October 2021 and 9 December 2021
2. TrialTrove search of industry sponsored PhII - IV Schizophrenia Trials 2011 - 2021
For further information, contact:
Cambridge Cognition Holdings Plc Tel: 012 2381 0700
Matthew Stork, Chief Executive Officer press@camcog.com
Sally Jennings, Head of Marketing & Communications
finnCap Ltd (NOMAD and Joint Broker) Tel: 020 7220 0500
Geoff Nash / Simon Hicks (Corporate Finance)
Alice Lane / Charlotte Sutcliffe (Corporate Broking)
Dowgate Capital Limited (Joint Broker) Tel: 020 3903 7715
David Poutney / James Serjeant
IFC Advisory Ltd (Financial PR and IR) Tel: 020 3934 6630
Tim Metcalfe / Graham Herring / Zach Cohen
Notes to Editors
About Cambridge Cognition
Cambridge Cognition is a technology company developing digital
health products to better understand, detect and treat conditions
affecting brain health. The Company's software products assess
cognitive health in patients worldwide to improve clinical trial
outcomes, identify and stratify patients early and improve global
efficiency in pharmaceutical and healthcare industries.
For further information visit www.cambridgecognition.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
CNTUPUUWGUPPGMM
(END) Dow Jones Newswires
January 10, 2022 02:00 ET (07:00 GMT)
Cambridge Cognition (LSE:COG)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Cambridge Cognition (LSE:COG)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024